Loading...
NPI 1386706174 · Bellevue, WA · Ophthalmology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Todd Klesert is a ophthalmology physician provider located in Bellevue, Washington. This profile covers 20 Medicare and 1 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Todd Klesert |
| Address | 1750 112th Ave Ne |
| City | Bellevue |
| State | WA |
| ZIP | 98004 |
| Taxonomy | Ophthalmology Physician |
| NPI Enumerated | December 15, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $2.1M |
| Medicaid | $0 |
This provider’s billing is effectively single‑payer in the dataset: lifetime Medicare revenue is $2.1M while Medicaid revenue is $0, so Medicare drives the entirety of reported public‑payer activity. The provider’s NPI was enumerated on 2006-12-15 (~20 years ago), indicating long tenure in the Medicare program and an established billing history.
Revenue is highly concentrated in a small set of intravitreal drug codes: the precomputed top three Medicare codes account for 76.6% of total Medicare revenue, with J0178 alone representing $1.2M (56.5% of Medicare revenue). The other two top contributors are J2777 ($274.9K, 13.0%) and Q5128 ($150K, 7.1%), underscoring dependence on anti‑VEGF and related injectable therapies as the primary revenue drivers.
The code mix indicates a retina‑focused ophthalmology practice that centers on intravitreal injections and associated diagnostics: large volumes of J0178, J2777, and Q5128 reflect regular anti‑VEGF/faricimab/rabizumab biosimilar administration, while high use of 92134 and the presence of surgical retina codes (67028, 67036, 67042) point to both non‑surgical injection management and some procedural retinal care. This combination is consistent with a practice model that manages chronic retinal disease through recurrent injections plus monitoring.
Competitive standing for the primary injection codes is mid‑to‑upper tier but not dominant nationally: J0178 ranks #667 of 3204 providers (79th percentile) and is described as typical, unremarkable volume; J2777 ranks #1044 of 2039 (49th percentile) and Q5128 ranks #185 of 373 (51th percentile), both also labeled typical, unremarkable volumes. In other words, the provider performs substantial injection work but does not appear as a national outlier or market leader for these specific drugs.
Diagnostic imaging is an outlier relative to peers: 92134 shows 1.9K claims and $59.6K revenue and ranks #1113 of 26868 providers (96th percentile), explicitly noted as notably above typical national volume. This suggests higher‑than‑average retinal imaging throughput and reporting capacity, supporting the injection‑centered care pathway with robust monitoring.
Office evaluation and management activity supports ongoing patient follow‑up: 99213 has 500 claims and $33K revenue (94th percentile) and 92014 has 455 claims and $42.8K revenue (83th percentile), indicating frequent established‑patient visits consistent with repeated injection schedules and monitoring visits. The presence of mid‑level E/M codes (99214, 99204) further signals a mixture of routine follow‑up and moderate complexity outpatient evaluations.
Ancillary and miscellaneous drug/supply billing appears in the mix but at modest levels: J3490 accounts for $79K (3.7%) with a $2194 avg paid/claim and ranks #2026 of 2838 providers (27th percentile), while compounded drug J7999 contributes $19.2K (0.9%) and ranks #368 of 1333 (72th percentile). Smaller volumes of surgical retina codes (67036, 67042) are present but do not drive revenue, indicating the practice is primarily outpatient/injection focused with occasional procedural cases.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
20 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 1,750 | $680 | $1.2M |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 9,480 | $30 | $274.9K |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 680 | $220 | $150K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 1,250 | $100 | $126.5K |
| J3490 | Unclassified drugs | 40 | $2,190 | $79K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 1,920 | $30 | $59.6K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 460 | $90 | $42.8K |
| J2778 | Injection, ranibizumab, 0.1 mg | 180 | $180 | $33.5K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 500 | $70 | $33K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 270 | $90 | $25.4K |
Showing 1–10 of 20
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 20 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
20 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J2777 | 29 | 50 | 12,780 | $30 | $599.7K |
| J0178 | 20 | 90 | 470 | $680 | $597.2K |
| Q5128 | 5 | 10 | 520 | $220 | $136.6K |
| J2778 | 23 | 30 | 510 | $180 | $117.1K |
| 67028 | 28 | 110 | 550 | $90 | $72.9K |
| J3490 | 44 | 70 | 70 | $50 | $51.2K |
| J7312 | 14 | 20 | 270 | $160 | $46K |
| 67042 | 36 | 40 | 30 | $1,190 | $39.2K |
| 67036 | 11 | 20 | 20 | $1,140 | $28.6K |
| 92014 | 101 | 790 | 110 | $80 | $16.8K |
Showing 1–10 of 20
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 10 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Washington providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Washington median
1 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 87 | 100 | 240 | $10 | $22.2K |
Other providers in the same ZIP code as Todd Klesert, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Universal Language Service, Inc. | WA | Contractor | $0 | $103.7M |
| Overlake Medical Center & Clinics | WA | General Acute Care Hospital | $0 | $16.6M |
| Daiya Healthcare PLLC | WA | Internal Medicine Physician | $0 | $8.7M |
| Steve Kim | WA | Ophthalmology Physician | $3.4M | $20 |
| David Saperstein | WA | Ophthalmology Physician | $3.3M | $100 |
| Andrew Barloon | WA | Ophthalmology Physician | $2.7M | $20 |
| Puget Sound Physicians PLLC | WA | Emergency Medicine Physician | $0 | $2.5M |
| Northwest Kidney Centers | WA | End-Stage Renal Disease (ESRD) Treatment Clinic/Center | $0 | $2.5M |
| Charles Birnbach | WA | Ophthalmology Physician | $2.4M | $0 |
| Robert Nash | WA | Ophthalmology Physician | $1.9M | $20 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.